Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
Combined Guanfacine and Mindfulness Meditation As an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
- Conditions
- MindfulnessGuanfacineOpioid Use Disorder
- Interventions
- Behavioral: Mindfulness Oriented Recovery Enhancement (MORE)
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 224
- Registration Number
- NCT06642181
- Locations
- 🇺🇸
Rutgers School of Health Professions, Newark, New Jersey, United States
Guanfacine for Alcohol Use Disorder (AUD)
- Conditions
- Alcohol Use Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 200
- Registration Number
- NCT06629259
- Locations
- 🇺🇸
Rutgers School of Health Professionals, Newark, New Jersey, United States
🇺🇸The Stark Neuroscience Building (Goodman Hall), Indianapolis, Indiana, United States
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 160
- Registration Number
- NCT06408246
- Locations
- 🇺🇸
Stanford Psychiatry and Behavioral Sciences Department, Palo Alto, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
- Conditions
- Hyperactivity in Children With Down SyndromeImpulsivity in Children With Down Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Rachel G. Greenberg, MD, MB, MHS
- Target Recruit Count
- 60
- Registration Number
- NCT06042257
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Guanfacine Extended-release for Adolescents With Cannabis Use
- Conditions
- Cannabis Use Disorder
- Interventions
- Behavioral: Residential withdrawalBehavioral: Engagement with alcohol and other drug servicesDrug: Placebo
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Orygen
- Target Recruit Count
- 100
- Registration Number
- NCT05957848
- Locations
- 🇦🇺
Orygen, Parkville, Victoria, Australia
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
- Conditions
- Prader-Willi SyndromeAggressionSelf-Injurious BehaviorPathologic ProcessesBehavioral SymptomsIntellectual DisabilityNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesAbnormalities, Multiple
- Interventions
- Other: Placebo
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Maimonides Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT05657860
- Locations
- 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study
- Conditions
- Critical IllnessDeliriumCognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 46
- Registration Number
- NCT04742673
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
The Effect of Guanfacine on Delirium in Critically Ill Patients
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 100
- Registration Number
- NCT04578886
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
Combining Varenicline and Guanfacine for Smoking Cessation
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Yale University
- Target Recruit Count
- 140
- Registration Number
- NCT04198116
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17418
- Registration Number
- NCT04113551
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.